300
N6F11 has been shown to degrade GPX4 in human pancreatic, bladder, breast and cervical cancer cells without affecting glutathione peroxidase in three vital immune system cell types: dendritic cells, T cells and neutrophils.
The discovery of this molecule will circumvent an important limitation of ferroptosis, which promotes the destruction of multiple cells in the tumor microenvironment, including immune cells.
